For well over a decade, policymakers have declared the healthcare system is moving towards value-based pricing of services and technologies. However, the movement from volume- to a value-based system of pricing has occurred at a snail's pace, especially in the pharmaceutical sector. Numerous barriers have prevented value-based pricing from being implemented.
Now, one of those barriers, namely Medicaid's "best price" rule, may change, to accommodate value-based pricing arrangements.
|